Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAG regimen in myelodysplastic syndrome with excess blasts (RAEB) in China
ChiCTR-TRC-10001148Phase 4Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 1990
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of homoharringtonine, cytarabine, filgrastim, decitabine and melphalan in myelodysplastic syndrome (MDS) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Hematologic response rate after 2 cycles, Overall survival and 2 more. Started Jan 1990; status: completed.
02
Drugs
homoharringtoninecytarabinefilgrastimdecitabinemelphalan
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR-TRC-10001148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001148.